Ekso Bionics Holdings, Inc. (EKSO) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Ekso Bionics Holdings, Inc. (EKSO) trades at $15.90 with AI Score 23/100 (Grade F). Ekso Bionics Holdings, Inc. designs, develops, and markets exoskeleton solutions for medical and industrial applications. Market cap: $38.6M, Sector: Healthcare.
Price as of Jul 20, 2026 · Last analyzed: May 8, 2026EKSO stock analysis for 2026: Analysts have set a consensus price target of $7.75 for Ekso Bionics Holdings, Inc., suggesting 51.3% downside from the current price of $15.90. The AI MoonshotScore is 23/100, indicating a strong bearish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
EKSO: 3/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Ekso Bionics Holdings, Inc. (EKSO) Healthcare & Pipeline Overview
Ekso Bionics Holdings, Inc. specializes in exoskeleton technology for medical rehabilitation and industrial augmentation, offering devices like EksoNR and EksoUE. The company operates globally, focusing on improving patient outcomes and worker productivity with its innovative wearable robotics, but faces challenges in profitability.
What Is the Investment Thesis for EKSO?
Ekso Bionics operates in a high-growth market for rehabilitation and human augmentation exoskeletons. Key value drivers include expanding applications of EksoNR in rehabilitation centers and increasing adoption of EksoWorks products in industrial settings. The company's gross margin of 52.9% indicates potential for profitability as sales scale. Upcoming catalysts include potential regulatory approvals for new medical applications and expansion of partnerships. However, the company's negative profit margin of -135.7% and reliance on external funding pose significant risks. Investors should monitor revenue growth, cost management, and progress towards profitability.
Based on FMP financials and quantitative analysis
EKSO Key Highlights
- Market Cap of $38.6M reflects its small-cap status and growth potential in the exoskeleton market.
- Gross Margin of 52.9% demonstrates strong pricing power and efficient production costs.
- Beta of 0.78 indicates lower volatility compared to the overall market, suggesting relative stability.
- Operates in two segments: EksoHealth and EksoWorks, diversifying its revenue streams across medical and industrial applications.
- Partnership with Lockheed Martin Corporation provides access to advanced technologies and expanded market opportunities.
Who Are EKSO's Competitors?
EKSO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| OMCL Omnicell, Inc. | $45.81 | -0.14% | $2.08B | 83 |
| ZTEK Zentek Ltd. | $0.46 | -2.13% | $49.5M | 63 |
| OMIC Singular Genomics Systems, Inc. | $20.01 | +0.00% | $50.8M | 61 |
| DXR Daxor Corporation | $10.91 | +0.05% | $55.0M | 58 |
| NYXH Nyxoah S.A. | $1.56 | -0.64% | $61.8M | 69 |
| PDEX Pro-Dex, Inc. | $54.66 | -4.74% | $175M | 81 |
| INFU InfuSystem Holdings, Inc. | $8.93 | +0.11% | $180M | 84 |
| UTMD Utah Medical Products, Inc. | $69.30 | -0.72% | $221M | 89 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are EKSO's Key Strengths?
- Innovative exoskeleton technology for medical and industrial applications.
- Established presence in the rehabilitation market with EksoNR.
- Strategic partnerships with Lockheed Martin and other industry leaders.
- Strong gross margin indicating pricing power.
What Are EKSO's Weaknesses?
- Negative profit margin and reliance on external funding.
- Limited market share compared to larger medical device companies.
- High R&D expenses and regulatory hurdles.
- Small employee base of 61 employees.
What Could Drive EKSO Stock Higher?
- Potential regulatory approvals for new medical applications of EksoNR.
- Expansion of partnerships with rehabilitation centers and industrial companies.
- Increasing adoption of exoskeletons in the workplace to reduce injuries.
- New product development and innovation in exoskeleton technology.
What Are the Key Risks for EKSO?
- Financial-distress signal — its Altman Z-Score of -19.13 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Negative profit margin and reliance on external funding.
- Competition from established medical device companies.
- Regulatory changes and reimbursement challenges.
- Economic downturns affecting healthcare spending.
- Technological obsolescence.
What Are the Growth Opportunities for EKSO?
- Expansion in Rehabilitation Centers: Ekso Bionics can increase its market penetration by targeting more rehabilitation centers with its EksoNR device. The market for rehabilitation robotics is projected to reach $1.8 billion by 2028, offering a substantial growth opportunity. By demonstrating the clinical benefits and cost-effectiveness of EksoNR, the company can drive adoption and generate recurring revenue through rentals and service contracts.
- Industrial Partnerships: The EksoWorks segment can leverage partnerships with industrial companies to deploy exoskeletons in manufacturing, construction, and logistics. The market for industrial exoskeletons is expected to reach $4.7 billion by 2030, driven by the need to reduce workplace injuries and improve productivity. Collaborating with industry leaders can provide access to large-scale deployments and valuable feedback for product development.
- Geographic Expansion: Ekso Bionics can expand its geographic footprint by entering new markets in Asia Pacific and Latin America. These regions offer significant growth potential due to increasing healthcare spending and rising awareness of exoskeleton technology. Establishing distribution networks and securing regulatory approvals in these markets will be crucial for successful expansion.
- New Product Development: Investing in R&D to develop new exoskeleton applications and improve existing products can drive long-term growth. The company can explore opportunities in areas such as geriatric care, sports medicine, and military applications. Innovation in sensor technology, AI algorithms, and wearable materials can enhance the performance and usability of exoskeletons.
- Telehealth Integration: Integrating telehealth capabilities into EksoNR can enable remote monitoring and therapy, expanding access to rehabilitation services. The telehealth market is growing rapidly, driven by the need for remote patient care and cost-effective healthcare solutions. By offering remote training and support, Ekso Bionics can differentiate itself from competitors and reach a wider patient population.
What Opportunities Does EKSO Have?
- Expansion into new geographic markets and applications.
- Increasing adoption of exoskeletons in industrial settings.
- Integration of AI and telehealth technologies.
- Growing demand for rehabilitation robotics.
What Threats Does EKSO Face?
- Competition from established medical device companies.
- Regulatory changes and reimbursement challenges.
- Economic downturns affecting healthcare spending.
- Technological obsolescence.
What Are EKSO's Competitive Advantages?
- Proprietary exoskeleton technology with patents protecting key innovations.
- Established brand reputation in the medical rehabilitation market.
- Strategic partnerships with leading hospitals and research institutions.
- First-mover advantage in specific exoskeleton applications.
What Does EKSO Do?
Ekso Bionics Holdings, Inc., founded in 2005 and headquartered in Richmond, California, designs, develops, sells, and rents exoskeleton products across the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates through two segments: EksoHealth and EksoWorks. The EksoHealth segment focuses on medical applications, designing, engineering, manufacturing, and marketing exoskeletons for rehabilitation. Their flagship product, EksoNR, is a wearable bionic suit used by physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury. EksoUE is an upper extremity assistive device that reduces the effect of gravity on the wearer's shoulders and arms. The EksoWorks segment caters to industrial applications, creating exoskeleton devices that allow able-bodied users to perform difficult, repetitive work for extended periods. Ekso Bionics has a license agreement with Lockheed Martin Corporation, enhancing its technological capabilities and market reach. The company's mission is to enhance human capabilities by pioneering the development of innovative exoskeleton solutions, addressing unmet needs in both healthcare and industrial sectors.
What Products and Services Does EKSO Offer?
- Designs and develops exoskeleton devices for medical rehabilitation and industrial use.
- Sells and rents exoskeleton products to hospitals, rehabilitation centers, and industrial companies.
- Provides the EksoNR, a wearable bionic suit for patients with brain, stroke, and spinal cord injuries.
- Offers the EksoUE, an upper extremity assistive device to reduce strain on shoulders and arms.
- Markets exoskeletons to able-bodied users in industrial settings to enhance physical capabilities.
- Enables physical therapists and physicians to treat patients with advanced rehabilitation technology.
How Does EKSO Make Money?
- Direct sales of exoskeleton devices to medical facilities and industrial clients.
- Rental programs for EksoNR and other products, providing recurring revenue.
- Service and maintenance contracts for installed exoskeletons.
- Licensing agreements for technology and intellectual property.
What Industry Does EKSO Operate In?
The medical instruments and supplies industry is experiencing growth driven by technological advancements and an aging population. The exoskeleton market, in particular, is expanding rapidly, fueled by increasing demand for rehabilitation solutions and workplace safety enhancements. Ekso Bionics competes with other companies in the robotics and medical device space, focusing on specialized exoskeleton applications. The industry is characterized by high regulatory hurdles and significant R&D investments. Market trends include the integration of AI and IoT technologies into medical devices to improve patient outcomes and operational efficiency.
Who Are EKSO's Key Customers?
- Hospitals and rehabilitation centers using EksoNR for patient therapy.
- Industrial companies deploying EksoWorks exoskeletons to improve worker safety and productivity.
- Physical therapists and physicians who utilize Ekso devices in their practice.
- Patients recovering from stroke, spinal cord injury, and other neurological conditions.
Company Profile
Ekso Bionics Holdings, Inc. operates in the Healthcare Equipment & Supplies industry within the Healthcare sector. It is headquartered in San Rafael, US. The company is led by CEO Scott G. Davis. EKSO has traded publicly since 2014.
How Ekso Bionics Holdings, Inc. Is Valued
Ekso Bionics Holdings, Inc. carries a market capitalization of $38.6M, placing it in the micro-cap category. Relative to its peer group, EKSO's quantitative score of 23/100 is below the peer average of 67/100.
Key Financial Metrics
Return on assets is -79.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -22.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.55 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -19.7%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 2/9Financial Health
Ekso Bionics Holdings, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -19.13 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project Ekso Bionics Holdings, Inc. revenue of about $19.4M for fiscal 2026, with EPS near $-0.10.
EKSO Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying indicates confidence in the company's growth potential, suggesting that executives believe in a positive future.
- Community sentiment has shifted positively as discussions around the company's innovative exoskeleton technology gain traction.
- An increase in partnerships with healthcare providers has sparked optimism about expanding market reach and revenue opportunities.
- Recent media coverage highlights the potential applications of Ekso's technology in rehabilitation, attracting interest from investors.
Bear Case
- Concerns about the competitive landscape persist, as new entrants in the exoskeleton market could dilute Ekso's market share.
- Social sentiment reflects skepticism over the pace of adoption in the healthcare sector, with some questioning the immediate demand for their products.
- Recent earnings reports showed slower-than-expected growth, raising doubts about the company's ability to scale effectively in the near term.
- There are ongoing regulatory challenges that could delay product launches, creating uncertainty among investors about future prospects.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
EKSO Latest News
No recent news available for EKSO.
EKSO Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for EKSO.
Price Targets
Consensus target: $7.75
EKSO MoonshotScore
What does this score mean?
The MoonshotScore rates EKSO 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Scott G. Davis
Unknown
Information about Scott G. Davis's background is not available in the provided context. Therefore, his career history, education, and previous roles are Unknown. Further research would be needed to provide a comprehensive biography.
Track Record: Information about Scott G. Davis's track record is not available in the provided context. Key achievements, strategic decisions, and company milestones under his leadership are Unknown. Further research would be needed to evaluate his performance.
EKSO Healthcare Stock FAQ
What does the AI Score mean for EKSO?
EKSO holds an AI Score of 23/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. Ekso Bionics Holdings, Inc. designs, develops, and markets exoskeleton solutions for medical and industrial applications. The company operates through EksoHealth and EksoWorks segments, providing …
What does Ekso Bionics Holdings, Inc. do?
Ekso Bionics Holdings, Inc. specializes in designing, developing, and marketing exoskeleton solutions for both medical rehabilitation and industrial applications. Through its EksoHealth segment, the company offers devices like EksoNR, a wearable bionic suit used in rehabilitation centers to assist patients recovering from stroke, spinal cord injury, and acquired brain injuries.
What do analysts say about EKSO stock?
Analyst coverage of Ekso Bionics Holdings, Inc. is limited, reflecting its small-cap status. Key valuation metrics such as price-to-earnings ratio are not applicable due to the company's current lack of profitability. Growth considerations center on the adoption rate of EksoNR in rehabilitation centers and the expansion of EksoWorks in industrial settings.
What are the main risks for EKSO?
Ekso Bionics faces several key risks, including its negative profit margin and reliance on external funding, which could impact its ability to invest in R&D and expand its operations. Competition from larger, more established medical device companies poses a threat to its market share. Regulatory changes and reimbursement challenges in the healthcare industry could also affect the adoption of EksoNR.
How does Ekso Bionics Holdings, Inc. navigate regulatory approval processes?
Ekso Bionics Holdings, Inc. must navigate complex regulatory pathways to commercialize its medical devices, primarily through the FDA in the United States and similar bodies in international markets. The company's strategy involves rigorous clinical trials to demonstrate the safety and efficacy of its products, followed by submission of premarket approval (PMA) or 510(k) applications, depending on the device classification.
What revenue streams does Ekso Bionics Holdings, Inc. have in healthcare?
Ekso Bionics Holdings, Inc. generates revenue in the healthcare sector primarily through the sale and rental of its EksoNR exoskeleton. Revenue streams include direct sales of the device to rehabilitation centers and hospitals, as well as recurring revenue from rental programs and service contracts. Additional revenue is derived from training and support services provided to healthcare professionals.
What are the key factors to evaluate for EKSO?
Ekso Bionics Holdings, Inc. (EKSO) holds an AI score of 23/100 (low). Analysts target $7.75 (-51%). Not financial advice.
How frequently does EKSO data refresh on this page?
EKSO's price was last updated on Jul 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven EKSO's recent stock price performance?
Ekso Bionics Holdings, Inc. (EKSO) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative exoskeleton technology for medical and industrial applications. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on provided sources and may not reflect the most recent developments.
- Financial data is limited and may not be comprehensive.